In the version of the article published in print, the legends for Figures 3 and 4 were published in the incorrect order. These errors have been corrected for the HTML and PDF versions of the article published online.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2015.103
Rights and permissions
About this article
Cite this article
Llovet, J., Villanueva, A., Lachenmayer, A. et al. Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12, 436 (2015). https://doi.org/10.1038/nrclinonc.2015.121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.121
This article is cited by
-
Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma
Scientific Reports (2023)
-
TrkB inhibition of DJ-1 degradation promotes the growth and maintenance of cancer stem cell characteristics in hepatocellular carcinoma
Cellular and Molecular Life Sciences (2023)
-
Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma
BMC Cancer (2022)
-
Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens
Nature Communications (2022)
-
TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma
Cell Death & Disease (2022)
